Focal Adhesion Kinase Provides a Collateral Vulnerability That Can Be Leveraged to Improve mTORC1 Inhibitor Efficacy

SIMPLE SUMMARY: While the PI3K/AKT/mTORC1 pathway is highly active in breast cancer, mTORC1-targeting drugs are not effective in all breast cancer subtypes. To identify potential resistance mechanisms, we utilized a mouse model of breast cancer that continues to grow in the presence of the mTORC1 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuellar-Vite, Leslie, Weber-Bonk, Kristen L., Abdul-Karim, Fadi W., Booth, Christine N., Keri, Ruth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323520/
https://www.ncbi.nlm.nih.gov/pubmed/35884439
http://dx.doi.org/10.3390/cancers14143374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323520/
https://www.ncbi.nlm.nih.gov/pubmed/35884439
http://dx.doi.org/10.3390/cancers14143374

Ejemplares similares